Probiodrug and Synt:em announce collaboration to develop compounds for certain drug targets for CNS
Further US-patent issued
Halle (Saale), Germany //
Probiodrug AG announced today that the company has concluded its first in man dosing study of P93/01, its lead candidate to be developed for the treatment of type 2 diabetes. P93/01 is one of a number of proprietary DPIV-inhibitor molecules which showed promising safety and efficacy in preclinical studies.
Probiodrug AG is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of the actions of Dipeptidyl Peptidase IV and related enzymes.
Konrad Glund, Ph.D.
D-06120 Halle (Saale)
Tel.: +49 345 55599-00
Fax: +49 345 55599-01